The Smad7-Skp2 complex orchestrates Myc stability, impacting on the cytostatic effect of TGF-betaopen access
- Authors
- Kim, Tae-Aug; Kang, Jin Muk; Hyun, Ja-Shil; Lee, Bona; Kim, Staci Jakyong; Yang, Eun-Sung; Hong, Suntaek; Lee, Ho-Jae; Fujii, Makiko; Niederhuber, John E.; Kim, Seong-Jin
- Issue Date
- Jan-2014
- Publisher
- COMPANY OF BIOLOGISTS LTD
- Keywords
- Myc; Smad7; Skp2; Protein stability; Ubiquitylation
- Citation
- JOURNAL OF CELL SCIENCE, v.127, no.2, pp 411 - 421
- Pages
- 11
- Journal Title
- JOURNAL OF CELL SCIENCE
- Volume
- 127
- Number
- 2
- Start Page
- 411
- End Page
- 421
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/11024
- DOI
- 10.1242/jcs.136028
- ISSN
- 0021-9533
1477-9137
- Abstract
- In most human cancers the Myc proto-oncogene is highly activated. Dysregulation of Myc oncoprotein contributes to tumorigenesis in numerous tissues and organs. Thus, targeting Myc stability could be a crucial step for cancer therapy. Here we report Smad7 as a key molecule regulating Myc stability and activity by recruiting the F-box protein, Skp2. Ectopic expression of Smad7 downregulated the protein level of Myc without affecting the transcription level, and significantly repressed its transcriptional activity, leading to inhibition of cell proliferation and tumorigenic activity. Furthermore, Smad7 enhanced ubiquitylation of Myc through direct interaction with Myc and recruitment of Skp2. Ablation of Smad7 resulted in less sensitivity to the growth inhibitory effect of TGF-beta by inducing stable Myc expression. In conclusion, these findings that Smad7 functions in Myc oncoprotein degradation and enhances the cytostatic effect of TGF-beta signaling provide a possible new therapeutic approach for cancer treatment.
- Files in This Item
-
Go to Link
- Appears in
Collections - 약학대학 > 약학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.